A Study to Assess Dynamic Changes in Plasma Proteome to Identify Early Detection and Treatment Response Biomarkers for HGSOC


About this study

This study aims to identify candidate High Grade Serous Cancer (HGSC) early detection and chemotherapy treatment response biomarkers.  For the purpose of this study we define high grade serous cancers to include invasive cancers arising in the ovary and/or fallopian tubes (FT).  Using mass spectrometry we will deeply profile and quantitate dynamic changes in the plasma proteome and N-gylcocapture sub-proteome that occur as a consequence of surgical debulking and platinum-based chemotherapy.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients must be English language proficient.
  • Patients must be > 18 years old.
  • Must be able to provide informed consent.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2.

NAC Cohort

  • ​​​​​​​Newly Diagnosed stage III or IV invasive serous ovarian cancer, grades 2, 3 or poorly differentiated. 

PD Cohort

  • Patients with an 75% or greater probability of having advanced HGSC based on the clinical judgement of investigator after review of imaging and CA 125 values and who are schedule to undergo a PD surgery;
  • Patients who have advanced HGSC confirmed at PD surgery and who undergo any attempt at surgical debulking will be considered eligible and enrolled in the PD cohort;
  • Patients with advanced HGSC confirmed at surgery and undergo diagnostic biopsy only without any debulking will be considered eligible and enrolled into the NAC cohort;
  • Patients who have benign ovarian disease confirmed at surgery will be considered eligible and enrolled as benign surgical controls (n=10 total). 
  • Scheduled to receive i.v. or combined i.v./i.p. platinum and taxane combination chemotherapy with or without bevacizumab within 4 weeks of study enrollment.
  • Patients must have Abdominal-Pelvic CT or MRI scan within 28 days of study enrollment
  • Organ function must include the following pre-treatment parameters: 
    • white blood count (WBC) > 3,000/ul;
    • Hb > 9 gm/dl %;
    • Platelet count > 100,000/ul;
    • serum creatinine < 1.5 mg/dl;
    • serum albumin > 3.5 gm/dl;
    • serum total bilirubin < 1.5 mg/dl;
    • alanine aminotransferase (ALT)/ aspartate aminotransferase (AST)/ alkaline phosphatase < 2 x ULN.

Exclusion Criteria:

  • Patients who have received treatment of any type including systemic chemotherapy, irradiation, hormonal treatment, immunotherapy, and/or debulking surgery for their ovarian cancer prior to study enrollment. 
  • Non-HGSC including adenocarcinomas of mucinous, clear cell, endometrioid or low-grade serous histology.
  • Borderline ovarian cancer of any histologic subtype.
  • Unable to provide bio-specimens as required by the study protocol.
  • Any medical conditions that increase risk of complications from a blood draw including hemophilia or other bleeding disorders or serious anemia.
  • Currently pregnant.
  • Inability to provide informed consent as assessed by the study investigator or research staff.
  • Other active malignancy defined as any treatment for invasive cancer of any type (excluding hormone therapy) within the last 5 years.  Exemptions include localized cancers that are considered to be cured by local excision or destructive measures (eg, basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix).
  • Concurrent participation in another research study is potentially allowed but requires formal PI review and approval to ensure it does not conflict with the goals of the current study. 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sun-Hee Lee, Ph.D.

Open for enrollment

Contact information:

Vonda Wall R.N.

(507) 266-2485


More information


Publications are currently not available

Mayo Clinic Footer